Notably, studies involving intracoronary delivery of recombinant TIMP-3 have shown promising outcomes in post-myocardial infarction (MI) remodeling, leading to reduced left ventricular (LV) dilation and lower levels of plasma NH2-terminal pro-brain natriuretic peptide, an established marker of heart failure progression [53]. The gene discussed is TIMP3; the disease is heart failure.